The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Role of apolipoprotein E in neurodegenerative diseases
Open accessAbstract
Apolipoprotein E (APOE) is a lipid-transport protein abundantly expressed in most neurons in the central nervous system. APOE-dependent alterations of the endocytic pathway can affect different functions. APOE binds to cell-surface receptors to deliver lipids and to the hydrophobic amyloid-β peptide, regulating amyloid-β aggregations and clearances in the brain. Several APOE isoforms with major structural differences were discovered and shown to influence the brain lipid transport, glucose metabolism, neuronal signaling, neuroinflammation, and mitochondrial function. This review will summarize the updated research progress on APOE functions and its role in Alzheimer's disease, Parkinson's disease, cardiovascular diseases, multiple sclerosis, type 2 diabetes mellitus, Type III hyperlipoproteinemia, vascular dementia, and ischemic stroke. Understanding the mutations in APOE, their structural properties, and their isoforms is important to determine its role in various diseases and to advance the development of therapeutic strategies. Targeting APOE may be a potential approach for diagnosis, risk assessment, prevention, and treatment of various neurodegenerative and cardiovascular diseases in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Feigin, V. L., Forouzanfar, M. H., Krishnamurthi, R., Mensah, G. A., Connor, M., Bennett, D. A., Moran, A. E., Sacco, R. L., Anderson, L., Truelsen, T., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61953-4 · Cited by 3,899
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095
High cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562 · cited 1×
“Recently, studies have showed that older patients with T2DM have a higher risk of cognitive dysfunction or dementia.(98) Moreover, T2DM was related not only to VD, but also to the clinical diagnosis of AD-type dementia.”
BackgroundCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499
Cholesterol homeostasis and function in neurons of the central nervous system
Pfrieger, F. W. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3018-7 · Cited by 453
Mahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
Zannis, V. I., Breslow, J. L., Utermann, G., Mahley, R. W., Weisgraber, K. H., Havel, R. J., Goldstein, J. L., Brown, M. S., Schonfeld, G., Hazzard, W. R., et al. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38094-9 · Cited by 436
Sanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., & Roses, A. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117407 · Cited by 404
Pathology and pathogenesis of vascular cognitive impairment—a critical update
Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353 · cited 1×
“It is difficult to distinguish the prevalence between VD and other pathologies, as 20%–30% of demented subjects show mixed pathologies.(57) Clinically, VD and AD share pathological features such as the presence of neurofibrillary tangles, amyloid plaques, whitematter lesions, and cerebral amyloid angiopathy.”
BackgroundAPOE distribution in world populations with new data from India and the UK
Singh, P. P., Singh, M., & Mastana, S. S. (2006) · Annals of Human Biology · doi:10.1080/03014460600594513 · Cited by 351
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.15.4696 · Cited by 345
Familial apolipoprotein E deficiency.
Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112704 · Cited by 313
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296
TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272
Ordovas, J. M., Litwack-Klein, L., Wilson, P. W., Schaefer, M. M., & Schaefer, E. J. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38690-9 · Cited by 238
Lalazar, A., Weisgraber, K. H., Rall, S. C., Giladi, H., Innerarity, T. L., Levanon, A. Z., Boyles, J. K., Amit, B., Gorecki, M., & Mahley, R. W. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68957-4 · Cited by 209
Kim, J., Jiang, H., Park, S., Eltorai, A. E. M., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., & Holtzman, D. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3773-11.2011 · Cited by 204 · cited 1×
“More recently, two reports have suggested that brain APOE regulates the clearance of amyloid-β (Aβ), which is a common hallmark of some neurological diseases.(18,19) So far, the mechanisms involving APOE in all of these biological processes have not been completely clarified.”
BackgroundBien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., & Huang, Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0033-12.2012 · Cited by 170
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165
Westerlund, J. A., & Weisgraber, K. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82318-3 · Cited by 164 · cited 1×
“critical for binding to VLDL particles, whereas binding to HDL occurs even without the carboxyl-terminal domain.(25)”
BackgroundApolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., Bersot, T. P., Mahley, R. W., & Blum, C. B. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111085 · Cited by 141
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Yang, D., Smith, J. D., Zhou, Z., Gandy, S. E., & Martins, R. N. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68020721.x · Cited by 111
Oikawa, S., Matsunaga, A., Saito, T., Sato, H., Seki, T., Hoshi, K., Hayasaka, K., Kotake, H., Midorikawa, H., Sekikawa, A., et al. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v85820 · Cited by 103
ApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Cladaras, C., Hadzopoulou-Cladaras, M., Felber, B. K., Pavlakis, G., & Zannis, V. I. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61655-2 · Cited by 92
Yamamura, T., Yamamoto, A., Sumiyoshi, T., Hiramori, K., Nishioeda, Y., & Nambu, S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111532 · Cited by 91
A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy
Matsunaga, A., Sasaki, J., Komatsu, T., Kanatsu, K., Tsuji, E., Moriyama, K., Koga, T., Arakawa, K., Oikawa, S., Saito, T., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00572.x · Cited by 91
Yin, Y.-W., Li, J.-C., Wang, J.-Z., Li, B.-H., Pi, Y., Yang, Q.-W., Fang, C.-Q., Gao, C.-Y., & Zhang, L.-L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.031 · Cited by 84
Association between APOE ε4 Allele and Vascular Dementia: The Cache County Study
Chuang, Y.-F., Hayden, K. M., Norton, M. C., Tschanz, J., Breitner, J. C. S., Welsh-Bohmer, K. A., Zandi, P. P., & for the Cache County Investigators (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000285166 · Cited by 81
Wardell, M. R., Weisgraber, K. H., Havekes, L. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30067-5 · Cited by 80
Apolipoprotein E ε4 Allele Is Associated with Vascular Dementia
Baum, L., Lam, L. C. W., Kwok, T., Lee, J., Chiu, H. F. K., Mok, V. C. T., Wong, A., Chen, X., Cheung, W. S., Pang, C. P., et al. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095246 · Cited by 57
Konishi, K., Saruta, T., Kuramochi, S., Oikawa, S., Saito, T., Han, H., Matsunaga, A., & Sasaki, J. (1999) · Nephron · doi:10.1159/000045513 · Cited by 54
Lohse, P., Mann, W. A., Stein, E. A., & Brewer, H. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99249-5 · Cited by 54
A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy
Ando, M., Sasaki, J., Hua, H., Matsunaga, A., Uchida, K., Jou, K., Oikawa, S., Saito, T., & Nihei, H. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00677.x · Cited by 53
Orth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1306 · Cited by 42
Kamboh, M. I., Aston, C. E., Perez-Tur, J., Kokmen, E., Ferrell, R. E., Hardy, J., & DeKosky, S. T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00129-9 · Cited by 40
Wardell, M., Rall, S., Schaefer, E., Kane, J., & Weisgraber, K. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42076-0 · Cited by 40
Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects
Mailly, F., Xu, C., Xhignesse, M., Lussier-Cacan, S., Talmud, P., Davignon, J., Humphries, S., & Nestruck, A. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42048-6 · Cited by 36
Hoffer, M. J. V., Niththyananthan, S., Naoumova, R. P., Kibirige, M. S., Frants, R. R., Havekes, L. M., & Thompson, G. R. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05819-4 · Cited by 32
ApoE gene polymorphism and vascular dementia in Chinese population: a meta-analysis
Liu, X., Li, L., Liu, F., Deng, S., Zhu, R., Li, Q., & He, Z. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0714-6 · Cited by 31
FEUSSNER, G., FUNKE, H., WENG, W., ASSMANN, G., LACKNER, K. J., & ZIEGLER, R. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01511.x · Cited by 28
Feussner, G., Scharnagl, H., Scherbaum, C., Acar, J., Dobmeyer, J., Lohrmann, J., Wieland, H., & März, W. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39106-9 · Cited by 21
Idenitification and characterization of a new variant of apolipoprotein E (apo E-Kochi).
SUEHIRO, T., YOSHIDA, K., YAMANO, T., & OHNO, F. (1990) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.29.587 · Cited by 17
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Van Giau, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 393
Self-citationSharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Neurodegenerative and neurological disorders by small inhaled particles
Heusinkveld, H. J., Wahle, T., Campbell, A., Westerink, R. H. S., Tran, L., Johnston, H., Stone, V., Cassee, F. R., & Schins, R. P. F. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.07.007 · Cited by 331
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277
Metadata
- Authors
- Van Giau, V., Bagyinszky, E., An, S. S., & Kim, S.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2015-07
- Volume
- 11
- Pages
- 1723
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W1606053795
- Cited by
- 171
- References
- 59
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.